Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

181. The WISDOM Study: breaking the deadlock in the breast cancer screening debate

The WISDOM Study: breaking the deadlock in the breast cancer screening debate 28944288 2018 11 13 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer The WISDOM Study: breaking the deadlock in the breast cancer screening debate. 34 10.1038/s41523-017-0035-5 There are few medical issues that have generated as much controversy as screening for breast cancer. In science, controversy often stimulates innovation; however, the intensely divisive debate over mammographic screening has had (...) the opposite effect and has stifled progress. The same two questions-whether it is better to screen annually or bi-annually, and whether women are best served by beginning screening at 40 or some later age-have been debated for 20 years, based on data generated three to four decades ago. The controversy has continued largely because our current approach to screening assumes all women have the same risk for the same type of breast cancer. In fact, we now know that cancers vary tremendously in terms

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

182. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. Importance: The results of the American College of Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial were first reported in 2005 with a median follow-up of 6.3 years. Longer follow-up was necessary because the majority of the patients had estrogen receptor-positive tumors that may recur (...) later in the disease course (the ACOSOG is now part of the Alliance for Clinical Trials in Oncology). Objective: To determine whether the 10-year overall survival of patients with sentinel lymph node metastases treated with breast-conserving therapy and sentinel lymph node dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to that of women treated with axillary dissection. Design, Setting, and Participants: The ACOSOG Z0011 phase 3 randomized clinical trial enrolled

JAMA2017

183. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy 28682681 2017 07 06 2017 09 15 2017 09 15 1527-7755 35 26 2017 Sep 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. De-Escalation Strategies in Human Epidermal Growth Factor (...) Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. 3046-3054 10.1200/JCO.2016.71.9815 Purpose Human

EvidenceUpdates2017

184. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial 28661759 2017 06 29 2017 09 08 2017 09 08 1527-7755 35 23 2017 Aug 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized (...) Trial. 2639-2646 10.1200/JCO.2017.72.3494 Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a standard for breast cancer. We evaluated a non-anthracycline-based regimen in TOP2A-normal patients. Patients and Methods In this multicenter, open-label, phase III trial, 2,012 women with early TOP2A-normal breast cancer and at least one high-risk factor were randomly assigned to receive six cycles of docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2

EvidenceUpdates2017

185. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, contro

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, contro 28600210 2017 06 10 2017 09 11 2017 09 11 1474-5488 18 7 2017 Jul The Lancet. Oncology Lancet Oncol. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy (...) for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. 929-945 S1470-2045(17)30404-7 10.1016/S1470-2045(17)30404-7 Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would

EvidenceUpdates2017

188. The Efficacy of Mindfulness Based Stress Reduction (MBSR) for Decreasing Anxiety and Depression among Breast Cancer Survivors

The Efficacy of Mindfulness Based Stress Reduction (MBSR) for Decreasing Anxiety and Depression among Breast Cancer Survivors "The Efficacy of Mindfulness Based Stress Reduction (MBSR) for Decreasi" by Haley J. Christensen and Danielle E. Marck > > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Breast cancer is one of the most common cancer diagnoses in women, where 1 (...) . The following review aims to determine the continuing efficacy of MBSR on reducing anxiety and depression among breast cancer survivors. Methods: An exhaustive search of available medical literature was performed using MEDLINE- Pubmed, Clinical Key, and Web of Science. Keywords used included: mindfulness, breast cancer, survivors, RCT, and MBSR. Studies were assessed for quality using GRADE criteria. Results: Thirty-seven articles were reviewed. After screening the titles and abstracts for eligibility

Pacific University EBM Capstone Project2017

189. Neratinib maleate (Nerlynx) - To reduce the risk of breast cancer returning

Neratinib maleate (Nerlynx) - To reduce the risk of breast cancer returning Nerlynx (neratinib maleate) Tablets U.S. Department of Health and Human Services Search FDA Submit search Nerlynx (neratinib maleate) Tablets Nerlynx Company: Puma Biotechnology, Inc. Application No.: 208051 Approval Date: 07/17/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: August 21

FDA - Drug Approval Package2017

190. Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy

Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy August 2017 Technology Description: Breast cancer, a cancer (...) that develops from the tissues of the breast, is the most common cancer in the UK. There are many types of breast cancer and they are often grouped based on the presence or absence of some specific types of proteins (‘receptors’) in the cells of the patient. The most common type of breast cancer are those that are hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). The advanced form of the HR+ and HER2- breast cancer occurs when the cancer has spread to other parts

NIHR Innovation Observatory2017

191. Current approach of the axilla in patients with early-stage breast cancer.

Current approach of the axilla in patients with early-stage breast cancer. The surgical approach of the axilla in patients with early-stage breast cancer has witnessed considerable evolution during the past 25 years. The previously undisputed gold standard of axillary-lymph-node dissection for staging has now been replaced by sentinel-lymph-node biopsy for patients with clinically negative axilla. For selected patients with limited sentinel-lymph-node involvement, completion axillary-lymph-node

Lancet2017

192. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy restricted to the vicinity (...) of the original tumour in women at lower than average risk of local relapse will improve the balance of beneficial versus adverse effects compared with whole-breast radiotherapy. METHODS: IMPORT LOW is a multicentre, randomised, controlled, phase 3, non-inferiority trial done in 30 radiotherapy centres in the UK. Women aged 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal adenocarcinoma of grade 1-3, with a tumour size of 3 cm or less (pT1-2), none to three positive

Lancet2017

193. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy 28580882 2017 06 05 2017 06 05 1527-7755 2017 Jun 03 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. JCO2017737585 10.1200/JCO (...) .2017.73.7585 Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC). Patients and Methods MONARCH 2 was a global, double-blind, phase III study of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who had progressed while receiving neoadjuvant or adjuvant endocrine

EvidenceUpdates2017

194. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial 28592386 2017 06 08 2017 07 31 1474-5488 18 7 2017 Jul The Lancet. Oncology Lancet Oncol. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. 917-928 S1470-2045(17)30434-5 10.1016/S1470-2045(17)30434-5 CT-P6 is a proposed biosimilar to reference (...) trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breast cancer. In this randomised, double-blind, active-controlled, phase 3 equivalence trial, we recruited women aged 18 years or older with stage I-IIIa operable HER2-positive breast cancer from 112 centres in 23 countries. Inclusion criteria were an Eastern Cooperative Oncology Group performance status score of 0 or 1; a normal left ventricular ejection

EvidenceUpdates2017

195. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial 28526536 2017 05 20 2017 07 28 1474-5488 18 6 2017 Jun The Lancet. Oncology Lancet Oncol. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis (...) of final overall survival results from a randomised, open-label, phase 3 trial. 732-742 S1470-2045(17)30312-1 10.1016/S1470-2045(17)30312-1 The antibody-drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Approval of this drug was based on progression-free survival and interim overall survival data from the phase 3 EMILIA study. In this report, we present a descriptive analysis

EvidenceUpdates2017

196. Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors

Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors 28628363 2017 06 19 2017 08 16 1527-7755 35 24 2017 Aug 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors. 2820-2828 10.1200/JCO.2016.71.9856 Purpose African American women with breast cancer have higher cancer-specific and overall mortality rates. Obesity is common (...) among African American women and contributes to breast cancer progression and numerous chronic conditions. Weight loss interventions among breast cancer survivors positively affect weight, behavior, biomarkers, and psychosocial outcomes, yet few target African Americans. This article examines the effects of Moving Forward, a weight loss intervention for African American breast cancer survivors (AABCS) on weight, body composition, and behavior. Patients and Methods Early-stage (I-III) AABCS were

EvidenceUpdates2017

199. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial 28479233 2017 05 08 2017 06 08 1474-5488 18 6 2017 Jun The Lancet. Oncology Lancet Oncol. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised (...) , phase 3 trial. 755-769 S1470-2045(17)30319-4 10.1016/S1470-2045(17)30319-4 The tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel. tAnGo was an international, open-label, randomised, phase 3 superiority trial

EvidenceUpdates2017

200. Myofascial techniques have no additional beneficial effects to a standard physical therapy programme for upper limb pain after breast cancer surgery: a randomized controlled trial

Myofascial techniques have no additional beneficial effects to a standard physical therapy programme for upper limb pain after breast cancer surgery: a randomized controlled trial 28523988 2017 05 19 2017 05 19 1477-0873 2017 May 01 Clinical rehabilitation Clin Rehabil Myofascial techniques have no additional beneficial effects to a standard physical therapy programme for upper limb pain after breast cancer surgery: a randomized controlled trial. 269215517708605 10.1177/0269215517708605 (...) To investigate the effects of myofascial techniques, in addition to a standard physical therapy programme for upper limb pain shortly after breast cancer surgery. Double-blinded (patient and assessor) randomized controlled trial with two groups. University Hospitals Leuven, Belgium Patients: A total of 147 patients with unilateral axillary clearance for breast cancer. All participants received a standard physical therapy programme starting immediately after surgery for four months. The intervention group

EvidenceUpdates2017